Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.